1-methyl-3-isobutylxanthine has been researched along with Parkinsonian Disorders in 1 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rangel-Barajas, C | 1 |
| Silva, I | 1 |
| García-Ramírez, M | 1 |
| Sánchez-Lemus, E | 1 |
| Floran, L | 1 |
| Aceves, J | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
1 other study available for 1-methyl-3-isobutylxanthine and Parkinsonian Disorders
| Article | Year |
|---|---|
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; | 2008 |